WO2005099756A3 - Antagonistes d'erbb pour le traitement de la douleur - Google Patents

Antagonistes d'erbb pour le traitement de la douleur Download PDF

Info

Publication number
WO2005099756A3
WO2005099756A3 PCT/US2005/011781 US2005011781W WO2005099756A3 WO 2005099756 A3 WO2005099756 A3 WO 2005099756A3 US 2005011781 W US2005011781 W US 2005011781W WO 2005099756 A3 WO2005099756 A3 WO 2005099756A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain therapy
erbb antagonists
erbb
antagonists
pain
Prior art date
Application number
PCT/US2005/011781
Other languages
English (en)
Other versions
WO2005099756A2 (fr
Inventor
David B Agus
Original Assignee
David B Agus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David B Agus filed Critical David B Agus
Priority to JP2007507499A priority Critical patent/JP4969440B2/ja
Priority to AT05734984T priority patent/ATE540696T1/de
Priority to CA2563341A priority patent/CA2563341C/fr
Priority to EP05734984A priority patent/EP1737489B1/fr
Priority to AU2005232657A priority patent/AU2005232657B2/en
Publication of WO2005099756A2 publication Critical patent/WO2005099756A2/fr
Publication of WO2005099756A3 publication Critical patent/WO2005099756A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'antagonistes d'ErbB, notamment des anticorps d'ErbB2, tels que rhuMAb 2C4, pour le traitement de la douleur.
PCT/US2005/011781 2004-04-08 2005-04-07 Antagonistes d'erbb pour le traitement de la douleur WO2005099756A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007507499A JP4969440B2 (ja) 2004-04-08 2005-04-07 疼痛治療のためのＥｒｂＢアンタゴニスト
AT05734984T ATE540696T1 (de) 2004-04-08 2005-04-07 Erbb2-antagonisten für die tumorschmerztherapie
CA2563341A CA2563341C (fr) 2004-04-08 2005-04-07 Antagonistes d'erbb pour le traitement de la douleur
EP05734984A EP1737489B1 (fr) 2004-04-08 2005-04-07 Antagonistes d' ErbB2 pour le traitement de la douleur tumorale
AU2005232657A AU2005232657B2 (en) 2004-04-08 2005-04-07 ErbB antagonists for pain therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56107604P 2004-04-08 2004-04-08
US60/561,076 2004-04-08

Publications (2)

Publication Number Publication Date
WO2005099756A2 WO2005099756A2 (fr) 2005-10-27
WO2005099756A3 true WO2005099756A3 (fr) 2006-06-15

Family

ID=35150505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011781 WO2005099756A2 (fr) 2004-04-08 2005-04-07 Antagonistes d'erbb pour le traitement de la douleur

Country Status (7)

Country Link
US (2) US20060034840A1 (fr)
EP (1) EP1737489B1 (fr)
JP (1) JP4969440B2 (fr)
AT (1) ATE540696T1 (fr)
AU (1) AU2005232657B2 (fr)
CA (1) CA2563341C (fr)
WO (1) WO2005099756A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
EP2248899B8 (fr) 2003-03-19 2015-07-15 Biogen MA Inc. Protéine de liaison du récepteur NOGO
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US8486893B2 (en) 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
UA90480C2 (uk) * 2004-07-22 2010-05-11 Джэнэнтэк, Инк. Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587519A1 (fr) * 2004-12-07 2006-06-15 Genentech, Inc. Selection de patients pour une therapie avec un inhibiteur de her
AU2005325200A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of HER antibodies
JP2008531576A (ja) * 2005-02-23 2008-08-14 ジェネンテック・インコーポレーテッド Ｈｅｒ二量体化阻害剤を使用した、ガン患者における疾患の進行までの期間または生存の延長
EP1904104B1 (fr) 2005-07-08 2013-09-11 Biogen Idec MA Inc. Anticorps anti-sp35 et leurs utilisations
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
AU2006320479B2 (en) 2005-12-02 2012-11-08 Biogen Ma Inc. Treatment of conditions involving demyelination
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
NZ578824A (en) 2007-03-02 2012-03-30 Genentech Inc Predicting response to a her dimerisation inhibitor based on low her3 expression
JP5674469B2 (ja) * 2007-10-11 2015-02-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド ＬＩＮＧＯ−１アンタゴニストおよびＴｒｋＢアゴニストの投与を介して圧力誘導性の視神経障害を処置し、神経変性を防ぎ、ニューロン細胞の生存を促進する方法
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
CN103813805B (zh) * 2011-07-06 2017-02-22 索兰徳特医院 Egfr靶向疗法
PE20142363A1 (es) 2011-10-14 2015-01-30 Genentech Inc Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
MX350957B (es) 2011-11-23 2017-09-27 Medimmune Llc Moleculas de union especificas para her3 y usos de las mismas.
US9071046B2 (en) 2012-01-10 2015-06-30 Hzo, Inc. Methods, apparatuses and systems for monitoring for exposure of electronic devices to moisture and reacting to exposure of electronic devices to moisture
US9146207B2 (en) 2012-01-10 2015-09-29 Hzo, Inc. Methods, apparatuses and systems for sensing exposure of electronic devices to moisture
US9527913B2 (en) 2012-05-02 2016-12-27 Symphogen A/S Humanized pan-HER antibody compositions
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
BR112015013849A2 (pt) * 2012-12-21 2017-07-11 Sykehuset Soerlandet Hf terapia direcionada a egfr de distúrbios neurológicos e dor
AU2014254086B2 (en) 2013-04-16 2018-07-05 Genentech, Inc. Pertuzumab variants and evaluation thereof
EP3022303B1 (fr) 2013-07-17 2023-11-01 Foundation Medicine, Inc. Méthodes de traitement de carcinomes urothéliaux
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
EP3581586A1 (fr) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Procédés de traitement d'un cancer du sein précoce à l'aide du trastuzumab-mcc-dm1 et du pertuzumab
EP3242893A1 (fr) 2015-01-08 2017-11-15 Biogen MA Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (fr) 2015-11-16 2017-05-26 Genentech, Inc. Procédés de traitement d'un cancer positif her2
AU2017355432A1 (en) 2016-11-04 2019-05-16 F. Hoffmann-La Roche Ag Treatment of HER2-positive breast cancer
CA3046092A1 (fr) 2016-12-28 2018-07-05 Genentech, Inc. Traitement du cancer exprimant her2 avance
DK3570884T3 (da) 2017-01-17 2020-11-30 Genentech Inc Subkutane HER2-antistofformuleringer
CN116850283A (zh) 2017-03-02 2023-10-10 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3615695A1 (fr) 2017-04-24 2020-03-04 Genentech, Inc. Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
WO2020115108A1 (fr) * 2018-12-06 2020-06-11 Sørlandet Sykehus Hf Inhibiteurs d'egfr et leur utilisation dans le traitement de la douleur neuropathique
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
AR125902A1 (es) * 2021-05-21 2023-08-23 Lilly Co Eli Compuestos y métodos dirigidos a epirregulina

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
WO2004048525A2 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
EP1400536A1 (fr) * 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0655924A4 (fr) 1992-06-30 1996-09-11 Oncologix Inc COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION.
CA2103323A1 (fr) 1992-11-24 1994-05-25 Gregory D. Plowman Tyrosine kinase du recepteur her4 humain
DK0616812T3 (da) 1993-03-24 2000-04-25 Berlex Biosciences Kombination af antihormonforbindelser og bindingsmolekyler til behandling af cancer
WO1994022478A1 (fr) 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION DE TUMEURS AVEC DES ANTICORPS MONOCLONAUX DIRIGES CONTRE L'ONCOGENE $i(NEU)
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
KR100754049B1 (ko) * 1999-06-25 2007-08-31 제넨테크, 인크. 전립선암을 치료하기 위한 약제 제조에 사용되는 항-ErbB2 항체 및 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
WO2004048525A2 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HEISS MARKUS M ET AL: "Immunotherapy of malignant ascites with trifunctional antibodies", INTERNATIONAL JOURNAL OF CANCER, vol. 117, no. 3, November 2005 (2005-11-01), pages 435 - 443, XP002367084, ISSN: 0020-7136 *
JAMES N D ET AL: "A Phase II Study of the Bispecific Antobody MDX-H210 (Anti-HER2 x CD64) with GM-CSF in HER2+ Advanced Prostate Cancer", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 2, 20 July 2001 (2001-07-20), pages 152 - 156, XP008031136, ISSN: 0007-0920 *
RATHORE RITESH ET AL: "Activated T Cells Armed with Anti-CD3 x Anti-HER2/neu Bispecific Antibody III. Kinetics and Survival of Armed ATC in Prostate Cancer Patients.", BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), & 44TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; PHILADELPHIA, PA, USA; DECEMBER 06-10, 2002, pages Abstract No. 3684, XP009061373, ISSN: 0006-4971 *
TAKAHASHI MASATO ET AL: "Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.", BREAST CANCER (TOKYO, JAPAN) 2003, vol. 10, no. 2, 2003, pages 170 - 174, XP009061300, ISSN: 1340-6868 *
XIONG HENRY Q ET AL: "Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 1 JUL 2004, vol. 22, no. 13, 1 July 2004 (2004-07-01), pages 2610 - 2616, XP009061496, ISSN: 0732-183X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Also Published As

Publication number Publication date
JP4969440B2 (ja) 2012-07-04
US20060034840A1 (en) 2006-02-16
EP1737489B1 (fr) 2012-01-11
US20110064737A1 (en) 2011-03-17
CA2563341A1 (fr) 2005-10-27
US8333964B2 (en) 2012-12-18
CA2563341C (fr) 2014-10-21
WO2005099756A2 (fr) 2005-10-27
AU2005232657A1 (en) 2005-10-27
EP1737489A2 (fr) 2007-01-03
AU2005232657B2 (en) 2010-12-16
ATE540696T1 (de) 2012-01-15
JP2007532566A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2005099756A3 (fr) Antagonistes d'erbb pour le traitement de la douleur
IL245462A0 (en) Antagonists of human origin against cmet
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
WO2005097832A3 (fr) Anticorps anti-tgf-$g(b) humanises
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2007073497A3 (fr) Antagonistes des canaux calciques
WO2007024705A3 (fr) Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
WO2005080429A3 (fr) Methodes de traitement de l'osteoarthrose avec des antagonistes de l'interleukine-6
WO2001000245A3 (fr) Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2007075852A3 (fr) Antagonistes du canal calcique
WO2003082208A8 (fr) Composes de pyrrolopyridazine et methodes d'utilisation de ces composes pour le traitement de maladies proliferatives
WO2005030144A3 (fr) Composes de pyrrolopyridazine, et procedes pour les utiliser pour traiter des troubles de proliferation
EP1773791A4 (fr) Composes pyrrolotriazine
WO2005023302A3 (fr) Traitement de troubles oculaires
WO2005065266A8 (fr) Composes de pyrrolotriazine disubstituee
WO2004055513A3 (fr) Utilisation d'antagonistes de cd137 pour le traitement de tumeurs
WO2007033140A3 (fr) Antagonistes prok2 et leurs procedes d'utilisation
WO2006016192A3 (fr) Polytherapie pour le traitement de la schizophrenie
TW200616631A (en) (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005232657

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2563341

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007507499

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005734984

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005232657

Country of ref document: AU

Date of ref document: 20050407

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005232657

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005734984

Country of ref document: EP